A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

Inclusion Criteria

• •Diagnosis of moderate to severe RA, defined as DAS28 greater than or equal to 3.7
• •Naive to tocilizumab, or received tocilizumab within 8 weeks prior to enrollment
• •Physician has made decision to commence IV or SC tocilizumab in accordance with label and reimbursement criteria
• •Treated with glucocorticoids for RA when starting tocilizumab treatment